The securities of Imagion Biosystems Limited (‘IBX’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of IBX, pending the release of an announcement regarding a capital raising.
Read the Suspension from Official Quotation announcement.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce